Hend El-Sherbini leads IDH to $111 million revenue in 2024

Key Points

• Integrated Diagnostics Holdings (IDH) reports a 39% revenue increase to $111.9 million in 2024, driven by higher test volumes.
• Profits soared 115% to EGP1.01 billion ($19.72 million), boosted by foreign exchange gains and reduced net interest expenses.
• IDH operates 628 laboratories across Egypt, Jordan, Sudan, and Nigeria, maintaining strong growth despite regional economic challenges.

Integrated Diagnostics Holdings (IDH), a leading healthcare services provider based in Cairo and headed by Egyptian businesswoman Hend El-Sherbini, posted impressive financial results for 2024, with revenue surpassing $110 million.

This growth, driven by an increase in test volumes, patient numbers, and higher revenue per test, highlights the company’s strong performance in the face of broader economic challenges.

Operational gains drive profit surge

According to its latest report, IDH’s revenue rose to EGP5.72 billion ($111.88 million) in 2024, up from EGP4.12 billion ($80.64 million) the previous year—an increase of 39 percent.

A 5 percent uptick in patient numbers helped lift profits, which jumped by 115 percent to EGP1.01 billion ($19.72 million). This was largely due to foreign exchange gains totaling EGP303 million and a 41 percent drop in net interest expenses, both of which strengthened the company’s bottom line.

Core markets continue to deliver

Egypt remains at the heart of IDH’s business, contributing EGP4.72 billion ($92.28 million), or 82.5 percent of the group’s total revenue. In Jordan, the Biolab unit brought in JOD13.9 million ($19.61 million), accounting for nearly 16 percent of overall earnings.

Meanwhile in Nigeria, Echo-Lab, although responsible for just 1.4 percent of revenue, recorded NGN2.72 billion ($1.7 million)—a 39 percent jump from the previous year, helped by a 60 percent rise in average revenue per test.

Steady expansion despite headwinds

IDH operates 628 laboratories across Egypt, Jordan, Sudan, and Nigeria, reinforcing its role as a major player in the region’s healthcare space. Even amid broader economic pressure, the company has kept expanding and building on its strategy to reach more patients and improve access to diagnostics.

Reflecting on the past year, Group CEO Hend El-Sherbini, who owns 26.71 percent of the company, said she’s optimistic about the road ahead. “We enter 2025 stronger and leaner, well-positioned to capture growth opportunities across our markets despite ongoing macroeconomic challenges,” she said.

Balance sheet strengthens

The company’s asset base also grew notably, rising by 23.55 percent to EGP7.13 billion ($139.44 million) at the end of 2024. Shareholders’ equity improved as well, climbing nearly 13 percent to EGP3.5 billion ($68.45 million), while retained earnings rose sharply—up 41.59 percent to EGP1.81 billion ($35.45 million).